Stock Information
symbol line chart

NEPHNephros Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Andrew Astor

Location

New Jersey, USA

Exchange

Nasdaq

Website

https://nephros.com

Summary

Nephros, Inc.

Company Info

CEO

Andrew Astor

Location

New Jersey, USA

Exchange

Nasdaq

Website

https://nephros.com

Summary

Nephros, Inc.

AI Insights for NEPH
5 min read

Quick Summary

Nephros, Inc. is a U.S.-based medical equipment company focused on high-performance water solutions for medical and commercial markets. The company operates through Water Filtration, Pathogen Detection, and Renal Products segments. Its core offering is ultrafiltration technology designed to remove biological contaminants from water and bicarbonate concentrate, especially in dialysis-related environments. Its main customers likely include dialysis centers, hospitals, healthcare facilities, and commercial users that require reliable water filtration and contamination control. The company is small, with about 30 employees, and its market capitalization is approximately $45.9 million, making it a micro-cap or penny-stock-style healthcare equipment business.

Strengths

•

Nephros’ main strength is its focus on specialized water filtration products for healthcare and commercial users that require high water quality.

•

Its ultrafiltration technology targets biological contaminants, which gives it relevance in dialysis centers and other sensitive medical environments.

•

The company is profitable in the provided period, with positive net income, positive operating income, and positive EPS.

•

Its gross profit of about $4.0 million on revenue of about $6.0 million suggests a strong gross margin profile for the quarter.

•

The company also benefits from being identified in recent coverage as a financially healthier penny stock, which can improve visibility among investors looking for small profitable companies.

Key Risks

•

Nephros faces risks from customer concentration, limited scale, and competition from larger filtration and medical equipment companies.

•

Because its revenue base is relatively small, the loss or delay of a few meaningful customer orders could materially affect quarterly results.

•

The company’s stock is also likely to remain volatile because of its small market capitalization, low trading volume, and penny-stock-style investor base.

•

Valuation risk is present because the shares already trade at earnings and EBITDA multiples that require continued execution.

What to Watch

During the most recent reported quarter, Nephros generated operating revenue of approximately $6.0 million and total gross profit of approximately $4.0 million.
The company also reported total operating income of about $1.2 million and net income of about $1.2 million, indicating profitability in the period.
Earnings per share were reported at $0.11 on both a basic and diluted basis.
The company’s sentiment rating was relatively high at about 76.68, which may reflect favorable market perception or improving financial health.
Recent third-party coverage also highlighted Nephros among penny stocks with solid financial health, little or no debt, improving profitability, and assets exceeding liabilities, although the article still noted that risks remain.

Price Drivers

•

Nephros’ stock price is likely driven by earnings results, revenue growth, and whether the company can sustain profitability.

•

The company reported basic and diluted EPS of $0.11, net income of about $1.2 million, operating income of about $1.2 million, and operating revenue of about $6.0 million for the referenced period.

•

Its valuation metrics show a price-to-earnings ratio of about 26.46, an EV-to-revenue ratio of about 2.01, and an EV-to-EBITDA ratio of about 24.29, so investors may be pricing in continued growth or margin stability.

•

The stock also has a beta of 1.556, suggesting it may move more sharply than the broader market, especially during risk-on or risk-off periods.

•

Recent market interest in financially healthier penny stocks has also been a driver, as Nephros was highlighted in coverage emphasizing small companies with solid balance sheets and improving profitability.

Recent News

•

Recent news coverage mentioned Nephros in a broader article about penny stocks with stronger financial profiles during a period of U.S. market volatility.

•

The article highlighted Nephros alongside Cricut and Dingdong as companies showing solid balance sheets, little or no debt, improving profitability, and assets exceeding liabilities.

•

This was not an announcement of a merger, acquisition, product launch, or partnership, but it did improve visibility for the company among investors screening for healthier small-cap names.

•

Other recent news items in the dataset focused on broader penny-stock themes and did not appear to be directly about Nephros.

•

Overall, the recent company-specific news tone is favorable but general, and it should not be interpreted as formal investment advice or a confirmed operating catalyst.

Market Trends

•

Nephros is affected by broader trends in healthcare safety, water quality, infection prevention, and small-cap investor sentiment.

•

Medical and commercial customers are increasingly focused on contamination control, which can support demand for filtration and pathogen-detection solutions.

•

At the same time, the market for penny stocks and micro-cap equities can be highly sensitive to interest rates, liquidity, risk appetite, and broader equity-market volatility.

•

Recent U.S. market strength has renewed investor interest in affordable growth stocks, especially those with healthier balance sheets and improving profitability.

•

However, if macro conditions weaken or investors rotate away from speculative small caps, Nephros’ valuation and trading momentum could come under pressure.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on NEPH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show